In a report sent to investors Tuesday, William Blair analyst John Sonnier reiterated an Outperform rating on Gilead Sciences (NASDAQ:GILD), following last week’s news that the FDA …
In a research report released Monday, William Blair analyst John Sonnier maintained an Outperform rating on Seattle Genetics (NASDAQ:SGEN), following today’s news that the …
In a research report released yesterday, William Blair analyst John Sonnier maintained an Outperform rating on Threshold Pharma (NASDAQ:THLD), in light of the …
In a research report issued Tuesday, William Blair analyst John Sonnier assigned an Outperform rating on Nektar Therapeutics (NASDAQ:NKTR), following the approval of NKTR’s …
In a research report issued yesterday, William Blair analyst John Sonnier maintained an Outperform rating on Exelixis (NASDAQ:EXEL). No price target provided.
In a research report released yesterday, William Blair analyst John Sonnier reaffirmed a Market Perform rating on Amgen Inc. (AMGN) on the heels …
In a research note issued today, William Blair analyst John Sonnier reiterated an Outperform rating on Threshold Pharmaceuticals (THLD), following the company’s second-quarter results, which were in line with the Street’s estimate. …
After the markets closed Monday,July 28, KaloBios Pharmaceuticals (KBIO) announced anagreement with Sanofi (SNY), which returns all rights to the KB001-A program. In addition, KaloBios …
In a research report released yesterday, William Blair analyst John Sonnier reiterated an Outperform rating on Exelixis Inc (EXEL). The report follows yesterday’s news of positive …
In a research report released yesterday, William Blair analyst John Sonnier reiterated an Outperform rating on Celgene Corporation (CELG) following yesterday’s news that the phase …
